Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
Background While prophylactic human papillomavirus (HPV) vaccines will certainly reduce the incidence of HPV-associated cancers, these malignancies remain a major health issue. PDS0101 is a liposomal-based HPV therapeutic vaccine consisting of the immune activating cationic lipid R-DOTAP and HLA-unr...
Main Authors: | Claire Smalley Rumfield, Y Maurice Morillon II |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-06-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/1/e000612.full |
Similar Items
-
Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009
by: Samuel T. Pellom, et al.
Published: (2021-04-01) -
Therapeutic Vaccines for HPV-Associated Malignancies
by: Smalley Rumfield C, et al.
Published: (2020-10-01) -
Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics
by: Vinayaka Kotraiah, et al.
Published: (2020-03-01) -
Using paclitaxel as an immunomodulator to enhance T cell-mediated therapeutic efficacy in lymphoma-bearing mice
by: Tzu-Chun Chen, et al.
Published: (2013) -
Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy
by: Brendon J. Coventry
Published: (2019-07-01)